Transdermal estrogen replacement therapy and plasma lipids in 693 French women

Maturitas

Volumn 30, Issue 3, 1998, Pages 265-272

  Bongard, Vanina ^a   Ferrières, Jean ^a   Ruidavets, Jean Bernard ^a   Amouyel, Philippe ^b   Arveiler, Dominique ^c   Bingham, Annie ^d   Ducimetière, Pierre ^d  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b INSTITUT PASTEUR DE LILLE   (France)

^c UNIVERSITÉ DE STRASBOURG   (France)

^d HÔPITAL BROUSSAIS   (France)

Author keywords

Clinical parameters; Coronary heart disease; MONICA survey

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; ESTRADIOL; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; ESTROGEN THERAPY; FEMALE; FRANCE; HEART PROTECTION; HUMAN; HYSTERECTOMY; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; OVARIECTOMY; POSTMENOPAUSE; REGRESSION ANALYSIS; TRANSDERMAL DRUG ADMINISTRATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADMINISTRATION, CUTANEOUS; ADULT; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; FRANCE; HUMANS; LINEAR MODELS; LIPIDS; MIDDLE AGED; POSTMENOPAUSE; QUESTIONNAIRES;

EID: 0032538987     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(98)00060-7     Document Type: Article

References (38)

1. Matthews K, Meilahn E, Kuller L, Kelsey S, Caggiula A, Wing R. Menopause and risk factors for coronary heart disease. New Engl J Med. 321:1989;641-646.
2. Jensen J, Nilas L, Christiansen C. Influence of menopause on serum lipids and lipoproteins. Maturitas. 12:1990;321-331.
3. Stevenson J, Crook D, Godsland I. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis. 98:1993;83-90.
4. Grady D, Rubin SM, Petitti DB et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Int Med. 117:1992;1016-1037.
5. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 20:1991;47-63.
6. Stampfer MJ, Colditz GA, Willett WC et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. New Engl J Med. 325:1991;756-762.
7. Bush TL, Barrett-Connor E, Cowan LD et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the lipid research clinics program follow-up study. Circulation. 75:1987;1102-1109.
8. Hammond CB, Jelovsek FR, Lee KL, Creasman WT, Parker RT. Effects of long-term estrogen replacement therapy. I. Metabolic effects. Am J Obstet Gynecol. 133:1979;525-536.
9. Sullivan JM, Van der Swaag R, Hughes JP et al. Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women. Arch Intern Med. 150:1990;2257-2262.
10. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med. 151:1991;75-78.
11. Wolf PH, Madans JH, Finucane FF, Higgins M, Kleinman JC. Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: evidence from a national cohort. Am J Obstet Gynecol. 164:1991;489-494.
12. Rozenbaum H. La ménopause en Europe. Birkhäuser MH, Rozenbaum H La Ménopause. Conférence Européenne de Consensus. 1995;13-19 Editions Eska, Paris.
13. Tunstall-Pedoe H. The World Health Organization MONICA Project (Monitoring of trends and determinants in Cardiovascular disease): a major international collaboraion. J Clin Epidemiol. 41:1988;105-113.
14. Böthig S. WHO-MONICA Project: objectives and design. Int J Epidemiol 1989; 18 (Suppl 1): S29-S37.
15. Tuomilehto J, Kuulasmaa K. WHO-MONICA Project: assessing CHD mortality and morbidity. Int J Epidemiol 1989; 18 (Suppl 1): S38-S45.
16. Tunstall-Pedoe H, Kuulasmaa K. Myocardial infarction and coronary deaths in the World Health Organisation MONICA Project. Circulation. 90:1994;583-612.
17. Friedwald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem. 18:1978;499-502.
18. SAS Institute Inc: SAS user's guide: statistics version. 5th ed. Cary, NC: SAS Institute Inc., 1985: 956.
19. Folsom AR, McGovern PG, Nabulsi AA et al. Changes in plasma lipids and lipoproteins associated with starting or stopping postmenopausal hormone replacement therapy. Am Heart J. 132:1996;952-958.
20. The Writing Group for the PEPI Trial Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. J Am Med Assoc. 273:1995;199-208.
21. Nabulsi AA, Folsom AR, White A et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. New Engl J Med. 328:1993;1069-1075.
22. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentration and metabolism of plasma lipoproteins. New Engl J Med. 325:1991;1196-1204.
23. Barrett-Connor E, Wingard DL, Criqui MH. Postmenopausal estrogen use and heart disease risk factors in the 1980s. J Am Med Assoc 1989; 261: 2095-100.
24. Crook D, Cust MP, Gangar KF et al. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol. 166:1992;950-955.
25. Tikkanen MJ. The menopause and hormone replacement therapy: lipids, lipoproteins, coagulation and fibrinolytic factors. Maturitas. 23:1996;209-216.
26. Hirvonen E, Malkonen M, Manninen V. Effects of different progestogens on lipoproteins during post-menopausal replacement therapy. New Engl J Med. 304:1981;560-563.
27. Notelovitz M, Gudat JC, Ware MD, Dougherty MC. Oestrogen-progestin therapy and the lipid balance of post-menopausal women. Maturitas. 4:1982;301-308.
28. Barrett-Connor E, Wingard DL, Criqui MH. Postmenopausal estrogen use and heart disease risk factors in the 1980s. J Am Med Assoc. 261:1989;2095.
29. Miller VT. Dyslipoproteinemia in women: special considerations. Endocrinol Metab Clin North Am. 19:1990;381-398.
30. Rijpkema AH, van der Sanden AA, Ruijis AH. Effects of post-menopausal oestrogen-progestogen replacement therapy on serum lipids and lipoproteins: a review. Maturitas. 12:1990;259-285.
31. Lobo RA, Pickar JH, Wild RA, Walsh B, Hirvonen E. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol. 84:1994;987-995.
32. Crook D, Seed M. Endocrine control of plasma lipoprotein metabolism: effects of gonadal steroids. Baillieres Clin Endocrinol Metab. 4:1990;851-876.
33. Triglyceride, high density lipoprotein, and coronary heart disease. NIH Consensus Statement J Am Med Assoc 1992; 10: 1-28.
34. Barrett-Connor E. Postmenopausal estrogen and prevention bias. Ann Int Med. 115:1991;455-456.
35. Posthuma WFM, Westendorp RGJ, Vandenbroucke JP. Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased? Br Med J. 308:1994;1268-1269.
36. Cauley JA, Cummings SR, Black DM, Mascioli SR, Seeley DG. Prevalence and determinants of estrogen replacement therapy in elderly women. Am J Obstet Gynecol. 163:1990;1438-1444.
37. Colditz GA, Stampfer MJ, Willett WC, Hennekens CH, Rosner B, Speizer FE. Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women. J Am Med Assoc 1990; 264-53.
38. Parazzini F, La Vecchia C, Negri E, Bianchi C, Fedele L. Determinants of estrogen replacement therapy use in northern Italy. Rev Epidem Sante Publ. 41:1993;53-58.